This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Monday's Health Winners & Losers

Health indices were generally flat Monday, but biotech stocks faced turbulence as takeover talk, study results, product problems and regulatory actions sent certain names all over the map.

Investors pumped Biogen Idec (BIIB) 18.8% to $82.51 Monday after the company announced post-close Friday that third parties -- including famed investor Carl Icahn -- had expressed interest in acquiring the company . Icahn reportedly made a $23 billion bid for the company.

Biogen's Tysabri partner Elan (ELN) gained ground Monday as well. The company, which has a 50% interest in the MS drug (which is also being reviewed for Crohn's disease), hired Lehman Brothers to advise on its options if Biogen is acquired by a third party. Elan said that under the terms of its agreement, it can acquire for fair value Biogen's 50% economic interest, sell its 50% interest, continue with the existing agreement or restructure the agreement in conjunction with a potential acquisition.

Elan rose $1.82, or 8%, to $24.17. Also, as if there weren't news enough, Biogen and Elan also said Monday that the Food and Drug Administration will take an additional three months to review Tysabri for use as a Crohn's disease treatment.

Speaking of regulatory action, Telik (TELK) added 48 cents, or 13.9%, to $3.94 after announcing that the FDA lifted a partial hold on Telcyta clinical trials, permitting the company to resume clinical development of the cancer drug.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ELN $0.00 0.00%
TELK $2.75 -8.33%
BIB $161.99 0.00%
MDT $77.38 0.00%
AAPL $123.25 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs